Blog Archives

PRESS RELEASE: Great Lakes NeuroTechnologies Launches Study to Automatically Classify Abnormal Muscle Tone in Movement Disorders

VIEW PRESS RELEASE [PDF]

15 JAN 2014: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today that it is launching a study to determine the feasibility of a clinician-worn glove to objectively evaluate abnormal muscle tone, such as stiff joints or muscle tightness,

Read more ›



PRESS RELEASE: Great Lakes NeuroTechnologies Secures $1.7 Million to Develop Continuous Dyskinesia Monitoring Technology for Parkinson’s Disease

VIEW PRESS RELEASE [PDF]

 05 Mar 2013: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today that they are launching commercialization and clinical studies to validate a system for objective, continuous monitoring of dyskinesias associated with Parkinson’s disease. The study is being funded by a $1,743,051 Phase II Small Business Innovative Research grant from the National Institutes of Health (NIH),

Read more ›



PRESS RELEASE: Great Lakes NeuroTechnologies Launches Study to Develop Intelligent Algorithms for Programming Deep Brain Stimulation in Parkinson’s

VIEW PRESS RELEASE [PDF]

22 JAN 2013: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today that they are launching a study to determine the feasibility of using intelligent algorithms to assist with programming deep brain stimulation settings for Parkinson’s disease.   The study is being funded by a $283,828 Phase I Small Business Innovative Research grant from the National Institutes of Health,

Read more ›



PRESS RELEASE: GLNT Tackles Continuous Monitoring of Essential Tremor with Launch of Multi-Site Clinical Study

VIEW PRESS RELEASE [PDF]

April 5, 2012: Valley View, OH Great Lakes NeuroTechnologies announced today they have launched a multi-site clinical study to assess continuous monitoring of essential tremor (ET) using their Kinesia technology platform. A preliminary study published in 2011 in the journal Parkinsonism and Related Disorders demonstrated that patient-worn motion sensors could detect tremor type and quantify tremor severity during both standardized tasks and non-standardized activities of daily living performed in a laboratory.

Read more ›



PRESS RELEASE: GLNT Begins Clinical Study to Demonstrate High Sensitivity Motor Symptom Detection in Parkinson’s Disease

VIEW PRESS RELEASE [PDF]

March 23, 2012: Valley View, OH Great Lakes NeuroTechnologies announced today that they have begun a clinical study to assess the sensitivity of their Kinesia system to detect subtle motor function changes in patients with Parkinson’s disease (PD).

Read more ›



PRESS RELEASE: The University of Rochester and Great Lakes NeuroTechnologies launch new clinical study to develop ambulatory dyskinesia assessment system

VIEW PRESS RELEASE [PDF]

Cleveland, OH – August 15, 2011 – Great Lakes NeuroTechnologies’ KinetiSense motion sensor technology will be used in a clinical study to capture and quantify dyskinesias (involuntary, irregular movements) caused by Parkinson’s disease (PD) medication. PD motor symptoms including tremor and bradykinesia are typically treated with levodopa.

Read more ›



PRESS RELEASE: Great Lakes NeuroTechnologies’ KinetiSense technology used in Parkinson’s disease gait and balance study

VIEW PRESS RELEASE [PDF]

Cleveland, OH – August 15, 2011 – Great Lakes NeuroTechnologies’ KinetiSense motion sensor technology was used in a clinical study to capture and quantify the effect of Deep Brain Stimulation (DBS) on gait and balance impairment in Parkinson’s disease (PD).

Read more ›



PRESS RELEASE: Great Lakes NeuroTech’s BioRadio and Vivonoetic Inc.’s VivoSense Used in Prematurity and Respiratory Outcomes Program Multicenter Study

VIEW PRESS RELEASE [PDF]

Cleveland, OH – August 1, 2011 – Great Lakes NeuroTech’s BioRadio and Vivonoetics Inc.’s VivoSense software are being used for the Prematurity and Respiratory Outcomes Program  (PROP, http://www.urmc.rochester.edu/pediatrics/pedsnews/july-10/prop.cfm) multicenter clinical study to examine the respiratory outcome of premature babies over the next three years.

Read more ›



PRESS RELEASE: CLEVEMED LAUNCHES CLINICIAL STUDY MONITORING PARKINSON’S DISEASE MOTOR SYMPTOMS IN THE CLINIC AND AT HOME USING KINESIA™

VIEW PRESS RELEASE [PDF]

CLEVELAND, Ohio (January 28, 2009) – Cleveland Medical Devices Inc. (CleveMed) has launched a large scale multicenter clinical study to continue development and validation of Kinesia™, a compact wireless system for monitoring severity of Parkinson’s disease (PD) motor symptoms. Kinesia uses miniature motion sensors worn on the hand and wirelessly transmits motor symptom information to a PC.

Read more ›



Top